<code id='052BB50427'></code><style id='052BB50427'></style>
    • <acronym id='052BB50427'></acronym>
      <center id='052BB50427'><center id='052BB50427'><tfoot id='052BB50427'></tfoot></center><abbr id='052BB50427'><dir id='052BB50427'><tfoot id='052BB50427'></tfoot><noframes id='052BB50427'>

    • <optgroup id='052BB50427'><strike id='052BB50427'><sup id='052BB50427'></sup></strike><code id='052BB50427'></code></optgroup>
        1. <b id='052BB50427'><label id='052BB50427'><select id='052BB50427'><dt id='052BB50427'><span id='052BB50427'></span></dt></select></label></b><u id='052BB50427'></u>
          <i id='052BB50427'><strike id='052BB50427'><tt id='052BB50427'><pre id='052BB50427'></pre></tt></strike></i>

          
          WSS
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion